John Kamholz , M.D., Ph.D.
John Kamholz, M.D., Ph.D., Professor in the Department of Neurology, is the director of the Huntington disease (HD) clinic, where he is involved in a number of neuroimaging studies attempting to identify biomarkers for disease progression. These data will be used to establish outcome measures for clinical trials in HD. He is currently the PI in two clinical trials for HD: LEGATO, sponsored by the Huntington Study Group to evaluate a monocloncal antibody to the protein Semaphorin 4B; and SIGNAL, sponsored by TEVA pharmaceuticals to evaluate the compound liquinimod. He is also the director of an adult Neurogenetics clinic where he is involved in the treatment, genetic diagnosis, and study of the natural history of patients with inherited ataxia syndromes, hereditary spastic parapareses, and other neurogenetic conditions. In addition, he is also PI of a project to analyze the neuroimaging, the molecular pathophysiology, and natural history of Pelizaeus-Merzbacher disease (PMD), an inherited demyelinating disease of the CNS, work supported by the European Leukodystrophy Association (ELA). This work, as a whole, is designed to provide clinical and neuroimaging data for use in the design of treatment trials for patients with neurodegenerative diseases.
In The News
May is Huntington's Disease month and a local news station recently featured John Kamholz, Director of the Huntington's Disease Center of Excellence at the University of Iowa, in a story about the center's efforts to educate local law enforcement on the symptoms of Huntington's since they...